Company Filing History:
Years Active: 2011
Title: Guoying Yu: Innovator in Cancer Diagnosis and Treatment
Introduction
Guoying Yu is a prominent inventor based in Kensington, CA (US). She has made significant contributions to the field of cancer-related genes, particularly through her innovative work on the SEMA4D gene. Her research focuses on methods for detecting cancer and the likelihood of developing cancer based on the presence or absence of this gene.
Latest Patents
Guoying Yu holds 1 patent related to her groundbreaking work. The patent addresses the SEMA4D gene in cancer diagnosis, detection, and treatment. This invention provides methods for identifying cancer and offers insights into upregulating or downregulating the SEMA4D gene, which could have profound implications for cancer therapies.
Career Highlights
Throughout her career, Guoying Yu has worked with notable organizations, including Novartis Vaccines & Diagnostics and Sagres Discovery. Her experience in these companies has allowed her to collaborate with leading experts in the field and contribute to advancements in cancer research.
Collaborations
Guoying has collaborated with talented individuals such as Albert Lai and Abdallah Fanidi. These partnerships have enriched her research and expanded the impact of her innovations in cancer diagnosis and treatment.
Conclusion
Guoying Yu's contributions to cancer research through her patent on the SEMA4D gene exemplify her dedication to improving cancer diagnosis and treatment. Her work continues to inspire advancements in the field and offers hope for better cancer management in the future.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.